Antitumoral activity of indole-3-carbinol cyclic tri- and tetrameric derivatives mixture in human breast cancer cells: In vitro and in vivo studies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 654-662

  Brandi, Giorgio ^a   Fraternale, Alessandra ^a   Lucarini, Simone ^a   Paiardini, Mirko ^b   De Santi, Mauro ^a   Cervasi, Barbara ^b   Paoletti, Maria F ^a   Galluzzi, Luca ^a   Duranti, Andrea ^a   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Breast cancer; CTr CTet; FOXO3a; GADD45A; I3C cyclic derivatives; LMW cyclin E; P21 CDKN1A; P27 CDKN1B

Indexed keywords

3 INDOLEMETHANOL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; METHANOL DERIVATIVE; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SOLUBILITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LD 50; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MCF-7 CELLS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84876702127     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313040014     Document Type: Article

References (48)

1. Higdon, J.V.; Delage, B.; Williams, D.E.; Dashwood, R.H. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol. Res., 2007, 55 (3), 224-36.
2. Minich, D.M.; Bland, J.S. A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals. Nutr. Rev., 2007, 65 (6 Pt 1), 259-67.
3. Verhoeven, D.T.; Goldbohm, R.A.; van Poppel, G.; Verhagen, H.; van den Brandt, P.A. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol. Biomarkers Prev., 1996, 5 (9), 733-48.
4. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin., 2011, 61 (2), 69-90.
5. Fahey, J.W.; Zhang, Y.; Talalay, P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl. Acad. Sci. U.S.A, 1997, 94 (19), 10367-72.
6. Zhang, Y. The molecular basis that unifies the metabolism, cellular uptake and chemopreventive activities of dietary isothiocyanates. Carcinogenesis, 2012, 33 (1), 2-9.
7. Aggarwal, B.B.; Ichikawa, H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle, 2005, 4 (9), 1201-15.
8. Weng, J.R.; Tsai, C.H.; Kulp, S.K.; Chen, C.S. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett., 2008, 262 (2), 153-63.
9. Cover, C.M.; Hsieh, S.J.; Cram, E.J.; Hong, C.; Riby, J.E.; Bjeldanes, L.F.; Firestone, G.L. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res., 1999, 59 (6), 1244-51.
10. Cover, C.M.; Hsieh, S.J.; Tran, S.H.; Hallden, G.; Kim, G.S.; Bjeldanes, L.F.; Firestone, G.L. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J. Biol. Chem., 1998, 273 (7), 3838-47.
11. Cram, E.J.; Liu, B.D.; Bjeldanes, L.F.; Firestone, G.L. Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J. Biol. Chem., 2001, 276 (25), 22332-40.
12. Rahman, K.M.; Aranha, O.; Glazyrin, A.; Chinni, S.R.; Sarkar, F.H. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene, 2000, 19 (50), 5764-71.
13. Bailey, G.S.; Hendricks, J.D.; Shelton, D.W.; Nixon, J.E.; Pawlowski, N.E. Enhancement of carcinogenesis by the natural anticarcinogen indole-3-carbinol. J. Natl. Cancer Inst., 1987, 78 (5), 931-4.
14. Kim, D.J.; Han, B.S.; Ahn, B.; Hasegawa, R.; Shirai, T.; Ito, N.; Tsuda, H. Enhancement by indole-3-carbinol of liver and thyroid gland neoplastic development in a rat medium-term multiorgan carcinogenesis model. Carcinogenesis, 1997, 18 (2), 377-81.
15. Pence, B.C.; Buddingh, F.; Yang, S.P. Multiple dietary factors in the enhancement of dimethylhydrazine carcinogenesis: main effect of indole-3-carbinol. J. Natl. Cancer Inst., 1986, 77 (1), 269-76.
16. Brandi, G.; Paiardini, M.; Cervasi, B.; Fiorucci, C.; Filippone, P.; De Marco, C.; Zaffaroni, N.; Magnani, M.A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res., 2003, 63 (14), 4028-36.
17. Lucarini, S.; De Santi, M.; Antonietti, F.; Brandi, G.; Diamantini, G.; Fraternale, A.; Paoletti, M.F.; Tontini, A.; Magnani, M.; Duranti, A. Synthesis and Biological Evaluation of a-Cyclodextrin-based Formulation of the Anticancer Agent 5,6,11,12,17,18,23,24-Octahydrocyclododeca [1,2-b:4,5-b':7,8-b″:10,11-b″']tetraindole (CTet). Molecules, 2010, 15, 4085-4093.
18. Lucarini, S.; Antonietti, F.; Tontini, A.; Mestichelli, P.; Magnani, M.; Duranti, A. A practical and expeditious method for the preparation of the anticancer agent 5,6,11,12,17,18,23,24-octahydrocyclododeca [1,2-b:4,5-b':7,8-b″:10,11-b″']tetraindole (CTet). Tetrahedron Lett., 2011, (52), 2812-4.
19. De Santi, M.; Galluzzi, L.; Lucarini, S.; Paoletti, M.F.; Fraternale, A.; Duranti, A.; De Marco, C.; Fanelli, M.; Zaffaroni, N.; Brandi, G.; Magnani, M. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. Breast Cancer Res., 2011, 13 (2), R33.
20. Galluzzi, L.; De Santi, M.; Crinelli, R.; De Marco, C.; Zaffaroni, N.; Duranti, A.; Brandi, G.; Magnani, M. Induction of Endoplasmic Reticulum Stress Response by the Indole-3-Carbinol Cyclic Tetrameric Derivative CTet in Human Breast Cancer Cell Lines. PLoS One, 2012, 7 (8), e43249.
21. Staub, R.E.; Bjeldanes, L.F. Convenient synthesis of 5,6,11,12,17,18-hexahydrocyclononal [1,2-b:4,5-b':7,8-b″]triindole, a novel phytoestrogen. J.Org. Chem., 2003, 68 (1), 167-9.
22. Beutler, E., A manual of biochemical methods, 3rd ed.; Grune and Stratton: New York, 1984.
23. Abukhdeir, A.M.; Park, B.H. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev. Mol. Med., 2008, 10, e19.
24. Liebermann, D.A.; Hoffman, B. Gadd45 in stress signaling. J. Mol. Signal, 2008, 3, 15.
25. Seoane, J., p21(WAF1/CIP1) at the switch between the anti-oncogenic and oncogenic faces of TGFbeta. Cancer Biol. Ther., 2004, 3 (2), 226-7.
26. Dijkers, P.F.; Medema, R.H.; Pals, C.; Banerji, L.; Thomas, N.S.; Lam, E.W.; Burgering, B.M.; Raaijmakers, J.A.; Lammers, J.W.; Koenderman, L.; Coffer, P.J. Forkhead transcription factor FKHR- L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell Biol., 2000, 20 (24), 9138-48.
27. Tran, H.; Brunet, A.; Grenier, J.M.; Datta, S.R.; Fornace, A.J., Jr.; DiStefano, P.S.; Chiang, L.W.; Greenberg, M.E. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science, 2002, 296 (5567), 530-4.
28. Myatt, S.S.; Lam, E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer, 2007, 7 (11), 847-59.
29. Yang, J.Y.; Hung, M.C. Deciphering the role of forkhead transcription factors in cancer therapy. Curr. Drug Targets, 2011, 12 (9), 1284-90.
30. Hu, M.C.; Lee, D.F.; Xia, W.; Golfman, L.S.; Ou-Yang, F.; Yang, J.Y.; Zou, Y.; Bao, S.; Hanada, N.; Saso, H.; Kobayashi, R.; Hung, M.C. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell, 2004, 117 (2), 225-37.
31. Yang, J.Y.; Zong, C.S.; Xia, W.; Yamaguchi, H.; Ding, Q.; Xie, X.; Lang, J.Y.; Lai, C.C.; Chang, C.J.; Huang, W.C.; Huang, H.; Kuo, H.P.; Lee, D.F.; Li, L.Y.; Lien, H.C.; Cheng, X.; Chang, K.J.; Hsiao, C.D.; Tsai, F.J.; Tsai, C.H.; Sahin, A.A.; Muller, W.J.; Mills, G.B.; Yu, D.; Hortobagyi, G.N.; Hung, M.C. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell Biol., 2008, 10 (2), 138-48.
32. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 1999, 96 (6), 857-68.
33. Coffer, P.J.; Jin, J.; Woodgett, J.R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J., 1998, 335 (Pt 1), 1-13.
34. Howells, L.M.; Gallacher-Horley, B.; Houghton, C.E.; Manson, M.M.; Hudson, E.A. Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol. Cancer Ther., 2002, 1 (13), 1161-72.
35. Rahman, K.M.; Li, Y.; Sarkar, F.H. Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr. Cancer, 2004, 48 (1), 84-94.
36. Rahman, K.W.; Sarkar, F.H. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res., 2005, 65 (1), 364-71.
37. Simoncini, T.; Hafezi-Moghadam, A.; Brazil, D.P.; Ley, K.; Chin, W.W.; Liao, J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature, 2000, 407 (6803), 538-41.
38. Ohtsubo, M.; Theodoras, A.M.; Schumacher, J.; Roberts, J.M.; Pagano, M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol., 1995, 15 (5), 2612-24.
39. Koff, A.; Giordano, A.; Desai, D.; Yamashita, K.; Harper, J.W.; Elledge, S.; Nishimoto, T.; Morgan, D.O.; Franza, B.R.; Roberts, J.M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science, 1992, 257 (5077), 1689-94.
40. Nanos-Webb, A.; Jabbour, N.A.; Multani, A.S.; Wingate, H.; Oumata, N.; Galons, H.; Joseph, B.; Meijer, L.; Hunt, K.K.; Keyomarsi, K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res. Treat, 2012, 132 (2), 575-88.
41. Koff, A.; Cross, F.; Fisher, A.; Schumacher, J.; Leguellec, K.; Philippe, M.; Roberts, J.M. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell, 1991, 66 (6), 1217-28.
42. Keyomarsi, K.; Tucker, S.L.; Buchholz, T.A.; Callister, M.; Ding, Y.; Hortobagyi, G.N.; Bedrosian, I.; Knickerbocker, C.; Toyofuku, W.; Lowe, M.; Herliczek, T.W.; Bacus, S.S. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med., 2002, 347 (20), 1566-75.
43. Keyomarsi, K.; O'Leary, N.; Molnar, G.; Lees, E.; Fingert, H.J.; Pardee, A.B. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res., 1994, 54 (2), 380-5.
44. Harwell, R.M.; Porter, D.C.; Danes, C.; Keyomarsi, K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res., 2000, 60 (2), 481-9.
45. Porter, D.C.; Keyomarsi, K., Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acid. Res., 2000, 28 (23), E101.
46. Akli, S.; Zheng, P.J.; Multani, A.S.; Wingate, H.F.; Pathak, S.; Zhang, N.; Tucker, S.L.; Chang, S.; Keyomarsi, K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res., 2004, 64 (9), 3198-208.
47. Wingate, H.; Puskas, A.; Duong, M.; Bui, T.; Richardson, D.; Liu, Y.; Tucker, S.L.; Van Pelt, C.; Meijer, L.; Hunt, K.; Keyomarsi, K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle, 2009, 8 (7), 1062-8.
48. Porter, D.C.; Zhang, N.; Danes, C.; McGahren, M.J.; Harwell, R.M.; Faruki, S.; Keyomarsi, K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol. Cell Biol., 2001, 21 (18), 6254-69.